Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alexandra Muir
Institution:
City Of Hope National Medical Center
Observed institution:
City Of Hope National Medical Center
ORCID:
0000-0003-3346-8892
Observed ORCID:
0000-0003-3346-8892
OpenAlex ID:
A5064765213
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
2023
·
Pallawi Torka
, Swetha Kambhampati Thiruvengadam
, et al.
·
Blood Cancer Journal
·
24
PDF
A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
2022
·
Geoffrey Shouse
, Tanya Siddiqi
, et al.
·
Blood
·
10
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial
2025
·
Geoffrey Shouse
, Canping Chen
, et al.
·
Haematologica
·
7
PDF
A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
2021
·
Geoffrey Shouse
, Tanya Siddiqi
, et al.
·
Blood
·
4
A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)
2022
·
Alexey V Danilov
, Alexandra Muir
, et al.
·
Blood
·
3
Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study
2021
·
Tanya Siddiqi
, Pamela Clay
, et al.
·
Blood
·
3
A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
2021
·
Pallawi Torka
, Swetha Kambhampati
, et al.
·
Blood
·
2
A chemotherapy‐free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma
2025
·
Paolo Lopedote
, Geoffrey Shouse
, et al.
·
British Journal of Haematology
·
1
Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)
2024
·
Paolo Lopedote
, Geoffrey Shouse
, et al.
·
Blood
PDF
Acalabrutinib, umbralisib and ublituximab regimen (AU2) demonstrates high response rate and undetectable molecular minimal residual disease (MRD) in patients (pts) with de novo mantle cell lymphoma (MCL)
2024
·
Paolo Lopedote
, Geoffry Shouse
, et al.
·
International Journal of Cancer Care and Delivery
PDF
Show more works
View as search
Works count:
10
Citation count:
54
H-index:
4
I10-index:
2
Year
Topic
Type